.jpg)
STAT+: This AI chat bot was trained on drag queens, and she wants to help protect your sexual health
A few months ago, a young Black gay patient in a southern state tapped out…
Category: STAT+
STAT+: After months of warnings, FTC opens investigation into Teva over ‘improper’ patents
The U.S. Federal Trade Commission is formally investigating Teva Pharmaceuticals after the company refused to…
STAT+: Steward Health Care spent millions on surveillance of its critics — even amid financial crisis
This story was reported by Hanna Krueger, Jessica Bartlett, Mark Arsenault, and Elizabeth Koh. It was written by Krueger…
STAT+: Novel amputation procedure makes walking with a prosthetic leg feel more seamless
A novel surgical technique could dramatically improve walking for people with below-the-knee amputations and help…
STAT+: Pharmalittle: We’re reading about indicted drug wholesalers, a gene therapy rejection, and more
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Ascension is racing to unload hospitals as execs work to stem losses
For 15 years, a formidable CEO-CFO duo often called “the two Tonys” ushered their St….
STAT+: Medicare’s big experiment to fix kidney failure care hasn’t worked so far, studies say
A few years ago, the Centers for Medicare and Medicaid Services launched a big experiment….
.jpg)
STAT+: Supreme Court’s gutting of Chevron doctrine could mean headaches for drug industry
The Food and Drug Administration’s power to make important regulatory decisions is in question after…
STAT+: Cassava Sciences collaborator charged with defrauding NIH in grants supporting its Alzheimer’s drug
A Cassava Sciences collaborator and paid consultant has been indicted by a federal grand jury…
STAT+: Drug wholesaler owners indicted for alleged role in diverting Gilead and J&J HIV medicines
The owners of a drug wholesaler have been indicted for their alleged role in a…
STAT+: Vape makers see Supreme Court ruling as a weapon in fighting FDA
WASHINGTON — Vape manufacturers are taking a victory lap over a Supreme Court decision that…
STAT+: Optum walks away from its agreement to buy Steward’s doctors network
Health care provider Optum has backed away from its plan to purchase Steward Health Care’s…
STAT+: Pharmalittle: We’re reading about the Purdue bankruptcy ruling, a Merck rejection, and more
And so, another working week will soon draw to a close. Not a moment too…
STAT+: FDA rejects Rocket Pharmaceuticals’ gene therapy for ultra-rare condition, another setback for field
Rocket Pharmaceuticals said Friday that the Food and Drug Administration rejected its gene therapy for…
STAT+: Don’t write off MDMA yet: How the FDA got on board with psychedelics
Days after an advisory committee resoundingly voted for the Food and Drug Administration to reject…
STAT+: Trying to outrun her prion disease, researcher creates powerful epigenetic editor in mice
Sonia Vallabh always thought genome editing wouldn’t be an option. It was such an obvious…
STAT+: Walgreens could shutter hundreds of underperforming stores
Walgreens is finalizing a plan to fix its U.S. business that could result in closing…
STAT+: Pharmalittle: We’re reading about EMA plans for GLP-1 shortages, Walgreens store closings, and more
Good morning, everyone, and how are you today? The heat continues to rise here on…
STAT+: Are expensive whole-body MRI scans medically useful? A new clinical trial aims to find out
A startup selling elective whole-body scans for upward of $1,000 is launching a 10-year, 100,000…
STAT+: Q&A: Defining responsible AI in health care, with CHAI CEO Brian Anderson
BEVERLY HILLS, Calif. — Artificial intelligence is increasingly infused into many aspects of health care,…
STAT+: Journal retracts study tied to Micronoma’s effort to create blood cancer test
Nature retracted a high-profile paper that served as part of the scientific groundwork for Micronoma,…
STAT+: Pharmalittle: We’re reading about rejection of an AbbVie Parkinson’s drug, PBM markups on mail order, and more
Hello, everyone, and how are you today? We are doing just fine, thank you, especially…
STAT+: Biotech accelerator Curie.Bio extends its reach with new $380 million fund
Industry veterans Alexis Borisy and Zach Weinberg had plenty of reasons to celebrate their new…
STAT+: Q&A: How Flagship’s Cellarity is using AI to understand cell disease biology before treating it
Flagship Pioneering launched Cellarity in December 2019. The startup says it’s using artificial intelligence and…
STAT+: Pharmalittle: We’re reading about Novo’s Wegovy approval in China, a Merck KGaA cancer trial failure, and more
Top of the morning to you, and a fine one it is. Clear blue skies…
STAT+: U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer
Pharmaceutical companies in the U.K. have increasingly violated a voluntary industry marketing code but complaints…
STAT+: Former Moderna executive launches genome editing company
As chief medical officer of Moderna, Tal Zaks used to be skeptical of genome editing….
STAT+: AliveCor gets FDA nod for portable 12-lead, AI-powered ECG device
AliveCor has spent years battling with Apple over the market for consumer heart monitoring technology….
Opinion: Could billions of dollars in AI funding lead to the same number of new drugs?
Drug discovery has quickly become the most enticing place to apply artificial intelligence. Billions of…
STAT+: Experts split on whether Eli Lilly’s Zepbound will hamper CPAP sales
Continuous positive airway pressure “is here to stay,” sleep medicine doctor Atul Malhotra declared in…
STAT+: Grail, aiming to launch a blood test for cancer, faces host of challenges as it debuts on Nasdaq
On Tuesday, shares of Grail, the liquid biopsy company that hopes that its test, Galleri,…
STAT+: HHS finalizes penalties for providers resorting to ‘information blocking’
The federal government has cemented a key part of its strategy for making patients’ medical…
STAT+: Oral ketamine tablets effective for treating depression, new study finds
The results of a randomized controlled trial published Monday showed oral ketamine tablets were safe…
STAT+: Steward Health Care executives are mired in trouble at home. In Malta, it’s much worse
VALLETTA, Malta — The most sweeping corruption trial in the history of this Mediterranean country…
STAT+: Pharmalittle: We’re reading about a plan for Medicare coverage of Wegovy, an Alnylam heart drug, and more
Good morning, everyone, to another working week. We hope the weekend respite was relaxing and…
STAT+: Alnylam reports positive results for heart drug in pivotal study, likely clearing path to approval
Alnylam Pharmaceuticals said Monday that its treatment for an increasingly common heart condition cut the…
STAT+: Ateev Mehrotra, the researcher the telehealth lobby loves to hate, isn’t backing down
WASHINGTON — He hardly seems the part of the telehealth industry’s public enemy No. 1….
STAT+: How the medical device tracking director at Kaiser Permanente weeds out risky devices
When a new medical device hits the market, there’s typically still some uncertainty about whether…
STAT+: The CEO of Kaiser’s new health network shares why he’s making a bet on a tiny North Carolina hospital system
Outside of North Carolina, most people probably haven’t heard of Cone Health. But the relatively…
STAT+: Jury orders Stanford to pay millions to employee in racial harassment case
A jury has found Stanford University and Stanford Health Care liable for millions of dollars…
STAT+: Vertex reports positive results in stem cell trial for type 1 diabetes
ORLANDO — Twelve people with type 1 diabetes who received a therapy derived from stem…
STAT+: House panel weighs new plan for Medicare coverage of Wegovy, cancer blood tests
WASHINGTON — A House panel is exploring holding a vote on scaled-back versions of two…
STAT+: Kaiser adds a small North Carolina health system to its Risant Health network
Kaiser Permanente on Friday announced the next deal to build out its Risant Health network…
STAT+: What the Sarepta decision means for Duchenne patients, the company, and the FDA
Sarepta Therapeutics always wins. That was a given, even before the Food and Drug Administration…
STAT+: Federal judge rules in favor of hospital lobby in privacy lawsuit
A federal judge has sided with a powerful hospital lobby in a legal battle with…
STAT+: Top FDA official Peter Marks overruled staff, review team to approve Sarepta gene therapy
For a third time, Sarepta Therapeutics has convinced a top Food and Drug Administration official…
STAT+: Ginkgo Bioworks lays off 158 employees, with more to come
BOSTON — Ginkgo Bioworks, the once-high-flying Boston life sciences firm, on Thursday said it has…
STAT+: FDA approves Sarepta’s Duchenne gene therapy for nearly all patients
The Food and Drug Administration on Thursday approved Elevidys, Sarepta’s gene therapy for Duchenne muscular…
STAT+: Vertex reaches a new deal with NHS England over its pricey cystic fibrosis treatments
After months of haggling, Vertex Pharmaceuticals and the National Health Service in England reached agreement…
STAT+: New immunotherapy combination could ‘change the landscape’ of cancer treatment
When they work, immunotherapy drugs called checkpoint inhibitors can shrink cancers and, in some cases,…